Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.58, $0.54 better than the analyst estimate of $1.04. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $55.65 million.

GUIDANCE:

Ligand Pharma sees FY2021 EPS of $5.80-$6.05, versus the consensus of $5.93. Ligand Pharma sees FY2021 revenue of $265-275 million, versus the consensus of $270 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.